Compare ACON & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACON | ENSC |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 7.6M |
| IPO Year | 2022 | 2017 |
| Metric | ACON | ENSC |
|---|---|---|
| Price | $2.29 | $0.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 61.1K | ★ 18.3M |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.82 | 65.24 |
| EPS | N/A | ★ N/A |
| Revenue | $75,730.00 | ★ $5,066,650.00 |
| Revenue This Year | $87.22 | $55.01 |
| Revenue Next Year | N/A | $1,033.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 65.62 | N/A |
| 52 Week Low | $1.95 | $0.23 |
| 52 Week High | $12.03 | $2.75 |
| Indicator | ACON | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 62.88 |
| Support Level | $1.95 | $0.34 |
| Resistance Level | $2.50 | $0.61 |
| Average True Range (ATR) | 0.18 | 0.03 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 8.62 | 93.78 |
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.